A Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy
Phase of Trial: Phase IV
Latest Information Update: 21 Nov 2018
At a glance
- Drugs Perampanel (Primary)
- Indications Epilepsy
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 21 Nov 2018 According to an Eisai Inc media release, data will be presented at the upcoming American Epilepsy Society Annual Meeting taking place from November 30 to December 4, 2018 in New Orleans.
- 06 Sep 2018 Planned End Date changed from 1 May 2019 to 1 Apr 2019.
- 27 Apr 2018 Interim analysis (n=187; safety analysis set) results assessing retention rate, dosing experience, and safety with perampanel administered to epilepsy patients during routine clinical care, presented at the 70th Annual Meeting of the American Academy of Neurology.